Alto Neuroscience, Inc.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith, who previously served as CFO since 2022, will now also oversee corporate strategy and business development while continuing to report to CEO Dr. Amit Etkin. Since joining as chief business officer in 2021, Mr. Smith has led the company's capital strategy, IPO, and the acquisition of ALTO-207.

•2mo ago

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience reported Q2 net loss of $27.6 million with cash of $244.2 million, bolstered by a July public offering that brings pro forma cash to approximately $338 million, funding operations into 2030. The company expanded its ALTO-207 development program by adding a planned Phase 3 monotherapy trial (PACE-3), complementing ongoing adjunctive trials, while an independent study published in Nature Medicine reinforced the drug's mechanism and tolerability rationale. Enrollment remains ongoing across the ALTO-300 and ALTO-100 Phase 2b trials, with topline data expected in the first half and mid-2027, respectively.

•2mo ago

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience highlighted a new Nature Medicine publication showing that pramipexole significantly reduces anhedonia in patients with mood disorders. The independent, placebo-controlled trial by Lund University found a significant effect on the primary endpoint (Hedges’ g=0.62, p=0.006), with benefits sustained through six months of open-label treatment. These findings reinforce the scientific basis for Alto’s lead asset ALTO-207, a combination of pramipexole and ondansetron designed to mitigate the nausea that limits pramipexole use. Data from Alto’s potentially pivotal Phase 2b trial in treatment-resistant depression is expected in the second half of 2027.

•4mo ago

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Alto Neuroscience appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors effective May 27, 2026. Miller led R&D at Karuna through its $14 billion acquisition by Bristol Myers Squibb and was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia. CEO Amit Etkin highlighted Miller’s experience in translating neuropsychiatric mechanisms into approved therapies as valuable for Alto’s pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression.

•5mo ago

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

Alto Neuroscience presented positive Phase 2a data for ALTO-207 in Major Depressive Disorder, showing statistically significant reductions in depressive symptoms versus placebo at Week 6 and Week 8. The trial demonstrated robust effect sizes (Cohen's d=1.67 at Week 6) and favorable tolerability, validating the drug's mechanism of pairing pramipexole with ondansetron to enable higher, more effective dosing. Based on these results, the company is advancing ALTO-207 into a potentially registrational Phase 2b trial in treatment-resistant depression, with topline data expected in the second half of 2027.

•6mo ago

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience initiated a Phase 2b trial of ALTO-207 for treatment-resistant depression (TRD), aiming to replicate strong efficacy signals from the PAX-D study and prior Phase 2a data. The trial will enroll approximately 178 adults and uses a MADRS primary endpoint aligned with FDA standards, potentially supporting a single Phase 3 registrational pathway. Topline data are expected in the second half of 2027.

•6mo ago